Sforza D, Iaria G, Tariciotti L, Manuelli M, Anselmo A, Ciano P, Manzia T M, Toti L, Tisone G
U.O.C. Chirurgia dei Trapianti, Fondazione Policlinico Tor Vergata, University of Rome "Tor Vergata", Rome, Italy.
Transplant Proc. 2013 Sep;45(7):2782-4. doi: 10.1016/j.transproceed.2013.07.004.
Immunologic alterations, such as cryoglobulinemia, have been described in the acute phase of primary cytomegalovirus (CMV) infections in immunocompetent patients. There are few references about these influences of a primary CMV infection in an at-risk kidney transplant recipient (donor positive/recipient negative-D(+)/R(-)). Herein we have described the case of a 46-year-old man, who was naive for CMV and underwent renal transplantation from a CMV+ cadaveric donor, thereby at high risk for disease transmission. The immunosuppression consisted of basiliximab, tacrolimus, mycophenolate mofetil, and steroids. The recipient was not treated with CMV prophylaxis, but rather regularly screened for possible pre-emptive treatment. At 35 days after transplantation, he was admitted because of deep vein thrombosis (DVT) in the transplant ipsilateral lower limb accompanied by oliguria, fever, and epigastric pain accompanied by type II cryoglobulinemia and acute CMV infection. The direct antiglobulin test (DAT) for C3d was positive. The cryoglobulins displayed anti-red blood cell specificity, with maximum activity at 4°C. The DVT was successfully treated with locoregional thrombolysis in combination with anticoagulant therapy. The DAT improved with CMV treatment and increased steroid therapy. The urine output and renal function tests improved with resolution of the thrombosis, achieving complete recovery without sequelae. Our hypothesis was that CMV infection triggered cryoglobulinemia. The blood disorder caused hyperviscosity, inducing DVT. This case, of CMV infection showed associated cryoglobulinemia presenting with antierythrocyte specificity in a kidney transplant recipient.
免疫改变,如冷球蛋白血症,已在免疫功能正常的患者原发性巨细胞病毒(CMV)感染急性期有所描述。关于原发性CMV感染对有风险的肾移植受者(供体阳性/受体阴性 - D(+)/R(-))的这些影响,相关参考文献较少。在此,我们描述了一名46岁男性的病例,他既往未感染过CMV,接受了来自CMV阳性尸体供体的肾移植,因此有很高的疾病传播风险。免疫抑制方案包括巴利昔单抗、他克莫司、霉酚酸酯和类固醇。受者未接受CMV预防治疗,而是定期进行筛查以便可能进行抢先治疗。移植后35天,他因移植侧下肢深静脉血栓形成(DVT)入院,伴有少尿、发热和上腹部疼痛,同时伴有II型冷球蛋白血症和急性CMV感染。C3d直接抗球蛋白试验(DAT)呈阳性。冷球蛋白显示出抗红细胞特异性,在4°C时活性最高。DVT通过局部溶栓联合抗凝治疗成功治愈。DAT随着CMV治疗和增加类固醇治疗而改善。随着血栓形成的消退,尿量和肾功能检查得到改善,实现了完全康复且无后遗症。我们的假设是CMV感染引发了冷球蛋白血症。血液疾病导致血液黏稠度增加,诱发了DVT。该CMV感染病例显示在肾移植受者中伴有具有抗红细胞特异性的冷球蛋白血症。